| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced-stage CRC incidence patterns following the phased implementation of the CRC screening programme in the Netherlands
|
Breekveldt, Emilie C.H.
|
|
|
178 |
C |
p. 60-67
|
artikel
|
| 2 |
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010–02)
|
Racadot, Séverine
|
|
|
178 |
C |
p. 114-127
|
artikel
|
| 3 |
A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target
|
Haslam, Alyson
|
|
|
178 |
C |
p. 227-233
|
artikel
|
| 4 |
Cancer care for Ukrainian refugees during the first 6 weeks of 2022 Russian invasion – An experience of a cancer reference centre in Poland
|
Püsküllüoğlu, Mirosława
|
|
|
178 |
C |
p. 234-242
|
artikel
|
| 5 |
Challenges of oncological care in Poland hosting Ukrainian refugees of war
|
Wyrwicz, Lucjan
|
|
|
178 |
C |
p. 243-244
|
artikel
|
| 6 |
Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study
|
Morfouace, Marie
|
|
|
178 |
C |
p. 216-226
|
artikel
|
| 7 |
Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer
|
Cocks, Kim
|
|
|
178 |
C |
p. 128-138
|
artikel
|
| 8 |
Corrigendum to ‘Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)’ [European Journal of Cancer 169 (2022) 1–9]
|
Li, Jiarui
|
|
|
178 |
C |
p. 247-248
|
artikel
|
| 9 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)
|
Sommerhäuser, Greta
|
|
|
178 |
C |
p. 37-48
|
artikel
|
| 10 |
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)
|
Sheng, Xinan
|
|
|
178 |
C |
p. 205-215
|
artikel
|
| 11 |
EORTC is 60 - and far from contemplating retirement
|
Van der Graaf, Winette
|
|
|
178 |
C |
p. 245-246
|
artikel
|
| 12 |
Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database
|
Margalit, Ofer
|
|
|
178 |
C |
p. 162-170
|
artikel
|
| 13 |
Head and neck cancer predictive risk estimator to determine control and therapeutic outcomes of radiotherapy (HNC-PREDICTOR): development, international multi-institutional validation, and web implementation of clinic-ready model-based risk stratification for head and neck cancer
|
van Dijk, Lisanne V.
|
|
|
178 |
C |
p. 150-161
|
artikel
|
| 14 |
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
|
Loibl, Sibylle
|
|
|
178 |
C |
p. 23-33
|
artikel
|
| 15 |
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer
|
Swain, Sandra M.
|
|
|
178 |
C |
p. 70-81
|
artikel
|
| 16 |
KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer
|
Xu, Jianming
|
|
|
178 |
C |
p. 1-12
|
artikel
|
| 17 |
Letter re: Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study
|
Yu, Yixuan
|
|
|
178 |
C |
p. 68-69
|
artikel
|
| 18 |
Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation
|
Boyle, Jemma M.
|
|
|
178 |
C |
p. 191-204
|
artikel
|
| 19 |
Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives
|
Ibrahim, Joe
|
|
|
178 |
C |
p. 91-113
|
artikel
|
| 20 |
PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer
|
Saw, Stephanie P.L.
|
|
|
178 |
C |
p. 139-149
|
artikel
|
| 21 |
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF V600 wild-type melanoma progressing on prior anti–programmed death-1 therapy
|
Sandhu, Shahneen
|
|
|
178 |
C |
p. 180-190
|
artikel
|
| 22 |
Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle
|
Antoun, Sami
|
|
|
178 |
C |
p. 49-59
|
artikel
|
| 23 |
Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience
|
Mueller, Timothy
|
|
|
178 |
C |
p. 171-179
|
artikel
|
| 24 |
Re: Effect of glioma-derived immunoglobulin on biological function of glioma cells: The emerging roles of immunoglobulins in the tumor immune microenvironment
|
Wu, Fei
|
|
|
178 |
C |
p. 34-36
|
artikel
|
| 25 |
Testing alternative schedules of adjuvant immune checkpoint blockers – The need for well-designed clinical trials
|
Bouche, Gauthier
|
|
|
178 |
C |
p. 88-90
|
artikel
|
| 26 |
The end of wide local excision (WLE) margins for melanoma ?
|
Zijlker, Lisanne P.
|
|
|
178 |
C |
p. 82-87
|
artikel
|
| 27 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101
|
Le Rhun, Emilie
|
|
|
178 |
C |
p. 13-22
|
artikel
|
Tijdschrift beschrijving